
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Protein-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Reliance Life Sciences has been granted authorization to undertake a phase 1 clinical study of its recombinant protein-based Covid-19 vaccine candidate by the Central Drugs Standard Control Organisation (CDSCOS)'s Expert Committee (SEC).
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Recombinant Protein-Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recombinant Protein Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reliance Life Sciences Seeks Approval for Phase I trial of its Covid Vaccine Candidate
Details : The aim of phase I clinical trials is to obtain reliable information on safety, tolerability, pharmacokinetics (PK), and mechanism of action of the recombinant protein based covid-19 vaccine with the objective of determining the maximum tolerated dose (M...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Recombinant Protein Based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Medicure
Deal Size : Undisclosed
Deal Type : Agreement
Details : The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 05, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Medicure
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Losartan Potassium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Pharmtechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 09, 2018
Lead Product(s) : Losartan Potassium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Pharmtechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
